UroGen Pharma (URGN) EBIT Margin (2017 - 2026)
UroGen Pharma (URGN) posted quarterly EBIT Margin of 39.76% for Q1 2026, up 14249.0% year-on-year from N/an in Q1 2025, and up 21.29% on a QoQ basis from 50.52% in Q4 2025.
UroGen Pharma (URGN) EBIT Margin (2017 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported EBIT Margin for 10 consecutive years, with 39.76% the latest figure, recorded in Q1 2026.
- Quarterly EBIT Margin rose 14249.0% year-over-year to 39.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 77.02% (up 4049.0% YoY) and the FY2025 annual result came in at 113.73%, down 667.0% from the prior year.
- EBIT Margin climbed to 39.76% in Q1 2026 per URGN's latest filing, from 50.52% in the prior quarter.
- Over the last five years, EBIT Margin for URGN reached as high as 39.76% in Q1 2026 and fell as low as 182.26% in Q1 2025.
- A 5-year average of 106.34% and a median of 112.36% in 2022 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin soared 18701 bps — and 2025, when it sank 5290 bps.
- Year by year, EBIT Margin stood at 112.1% in 2022, then jumped by 45 bps to 62.09% in 2023, then sank by 81 bps to 112.59% in 2024, then soared by 55 bps to 50.52% in 2025, then climbed by 21 bps to 39.76% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 39.76%, 50.52%, and 99.65% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | -39.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.76% |
| Dec 31, 2025 | -50.52% |
| Sep 30, 2025 | -99.65% |
| Jun 30, 2025 | -171.17% |
| Mar 31, 2025 | -182.26% |
| Dec 31, 2024 | -112.59% |
| Sep 30, 2024 | -69.61% |
| Jun 30, 2024 | -118.27% |
| Mar 31, 2024 | -137.05% |
| Dec 31, 2023 | -62.09% |
| Sep 30, 2023 | -64.74% |
| Jun 30, 2023 | -72.77% |
| Mar 31, 2023 | -128.23% |
| Dec 31, 2022 | -112.10% |
| Sep 30, 2022 | -112.36% |
| Jun 30, 2022 | -112.71% |
| Mar 31, 2022 | -161.88% |
| Dec 31, 2021 | -123.13% |
| Sep 30, 2021 | -206.50% |
| Jun 30, 2021 | -175.13% |